Potential biomarkers that can be used to determine prognosis and perform targeted therapies are urgently needed to treat patients with hepatocellular carcinoma (HCC). To meet this need, we performed a screen to identify functional genes associated with hepatocellular carcinogenesis and its progression at the transcriptome and proteome levels. We identified aldehyde dedydrogenase-2 (ALDH2) as a gene of interest for further study. ALDH2 levels were significantly lower at the mRNA and protein level in tumor tissues than in normal tissues, and they were even lower in tissues that exhibited increased migratory capacity. A study of clinical associations showed that ALDH2 is correlated with survival and multiple migration-associated clinicopathological traits, including the presence of metastasis and portal vein tumor thrombus. The result of overexpressing or knocking down ALDH2 showed that this gene inhibited migration and invasion both in vivo and in vitro. We also found that ALDH2 altered the redox status of cells by regulating acetaldehyde levels and that it further activated the AMP-activated protein kinase (AMPK) signaling pathway. Conclusion: Decreased levels of ALDH2 may indicate a poor prognosis in HCC patients, while forcing the expression of ALDH2 in HCC cells inhibited their aggressive behavior in vitro and in mice largely by modulating the activity of the ALDH2-acetaldehyde-redox-AMPK axis. Therefore, identifying ALDH2 expression levels in HCC might be a useful strategy for classifying HCC patients and for developing potential therapeutic strategies that specifically target metastatic HCC. (HEPATOLOGY 2017; 65:1628-1644).
H epatocellular carcinoma (HCC) is the thirdmost frequent cause of cancer-related deaths worldwide. (1) (2) (3) Treatments for HCC have continued to evolve over the last decade, and carefully selected patients can be effectively managed using hepatic resection, liver transplantation, and locoregional therapies. (4, 5) Additionally, cancer classifications that are based on molecular markers can be used to effectively predict recurrence and metastasis, which improves the ability of practitioners and patients to Abbreviations: ACE, acetaldehyde; AICAR, 5-aminoimidazole-4-carboxamide 1-b-D-ribofuranoside; ALDH2, aldehyde dedydrogenase-2; AMPK, AMP-activated protein kinase; AUC, area under curve; CREB, cAMP responsive element-binding protein; CYP2B6, cytochrome P450 2B6; DCXR, dicarbonyl/L-xylulose reductase; EMT, epithelial mesenchymal transition; FBS, fetal bovine serum; GFP, green fluorescent protein; GLYATL1, glycine-N-acyltransferase-like 1; HCC, hepatocellular carcinoma; IHC, immunohistochemical; iTRAQ, isobaric tags for relative and absolute quantitation; LV, lentiviral; MAH, metastasis-averse HCC; Met, metformin; MIH, metastasis-inclined HCC; MS/MS, tandem mass spectrometry; OS, overall survival; p-AMPK, phosphorylated AMPK; p-ERK, phosphorylated extracellular signal-regulated kinase; p-JNK, phosphorylated c-Jun N-terminal kinase; ppm, parts per million; PVTT, portal vein tumor thrombus; RNA-Seq, RNA sequencing; ROC, receiving operating character; siALDH2, ALDH2-specific siRNA; siRNAs, small interfering RNAs.
choose appropriate treatment options and thereby achieve better prognoses. (6) However, outcomes continue to be dismal in HCC because the rates of postsurgical recurrence and metastasis remain high. (7) Therefore, identifying more-reliable biomarkers that can be used to predict HCC progression and increase our understanding of the mechanisms underlying its progress will contribute to the development of better tumor treatment options and prolong survival in HCC patients.
Recently, metabolic alterations have been reported in tumor tissues. (8, 9) The results of several studies of HCC have shown that metabolic dysfunctions contribute to hepatocarcinogenesis and its development. (10, 11) Separately, a recent review suggested that differences in aldehyde dedydrogenase-2 (ALDH2) expression may contribute to a wide variety of human diseases, including cardiovascular diseases, diabetes, and cancer. (12) In addition, genetic polymorphisms of ALDH2 alter the susceptibility to ethanol intake and the risk of alcoholism and alcoholic complications, (13) and ALDH2 may possess important therapeutic potential against alcoholism and other forms of myocardial damage. (14) Nonetheless, the role of ALDH2 in the pathogenesis of HCC remains controversial, and the potential role of ALDH2 expression in HCC remains largely unknown.
In the current study, we found that ALDH2 levels were lower in HCC tissues than in corresponding normal tissues at both the mRNA and protein level. Even lower levels of ALDH2 were observed in tissues with increased migratory capacity. In addition, we demonstrate that there is a negative correlation between ALDH2 expression and malignant HCC traits in independent HCC cohorts. Finally, ectopically expressing ALDH2 dramatically decreased HCC metastasis both in vitro and in vivo. Further analysis showed that ALDH2 influences metastasis largely by modulating the ALDH2-acetaldehyde (ACE)-redox-AMPK (AMP-activated protein kinase) axis. 
Materials and Methods

PATIENTS AND SAMPLES
IN VITRO CELL BEHAVIOR ASSAYS
For the proliferation assays, HCCLM3-ALDH2, SMMC7721-ALDH2, and appropriate control cells were seeded in 200 lL of fresh medium into 96-well plates (3,000 cells/well) for various lengths of time. Cell viability was determined every 24 hours using a Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan), according to the manufacturer's instructions. For the wound-healing migration assays, monolayers of cells were plated in 12-well plates. Once the cells were attached, a wound was made by scraping a 200-uL plastic pipette tip along the bottom of the plate. Cells were then rinsed several times with medium to remove any floating cells. The wound-healing process was examined after 72 hours using an inverted light microscope (Olympus, Tokyo, Japan). Cell migration and invasion assays were performed using transwell filter chambers (Costar, Corning, NY) and BioCoat Matrigel invasion chambers (BD Biosciences, Franklin Lakes, NJ), according to the manufacturers' instructions. Briefly, 1 3 10 5 cells were resuspended in serum-free medium and then added to the top chamber. Medium supplemented with 10% fetal bovine serum (FBS) was added to the lower chamber. After 12 or 48 hours of incubation, the cells on the lower surface of the membrane were stained, photographed, and counted in six random fields per group using a microscope. These experiments were performed in triplicate. Cell adhesion assays were performed using a CytoSelect 24-Well Cell Adhesion Assay Kit (fibronectin coated), according to the manufacturer's instructions (CellBiolabs, San Diego, CA). (17) 
IN VIVO METASTASIS ASSAYS
All animal studies were approved by the Institutional Animal Care and Use Committee of the Second Military Medical University (Shanghai, China). In the pulmonary metastatic model, to evaluate the potential of the cells to metastasize to the lungs, eighteen 7-week-old male nude mice were randomized into two groups (n 5 9 each), and 1 3 10 6 control cells (SMMC7721-GFP) or SMMC7721 cells that stably expressed ALDH2 (SMMC7721-ALDH2) were trypsinized, resuspended in 0.2 mL of phosphatebuffered saline, and then injected into the tail vein using a 27-gauge needle. Mice were sacrificed at 10 weeks postinjection. Metastases were monitored in vivo using an IVIS@ Lumina II system (Caliper Life Sciences, Hopkinton, MA) and microscopically examined postsacrifice using hematoxylin and eosin staining to analyze the development of metastatic lung foci. Mouse survival was analyzed using a survival analysis. For the hepatic metastasis assay, nude mice spleens were inoculated with HCCLM3-ALDH2 or control cells (2 3 10 6 ), and the metastatic tumor colonies that developed in the liver were measured using an IVIS@ Lumina II system 12 weeks later. Animals were housed in cages under standard conditions according to the requirements of the Second Military Medical University Animal Care Facility and the National Institutes of Health (Bethesda, MD) guidelines.
CELL CULTURE, LENTIVIRUS, SMALL INTERFERING RNA
Normal liver cell line LO2 (also known as HL-7702) and liver cancer cell lines PLC/PRF/5, SMMC-7721, HCC-LM3, and PVTT were purchased from Cell Bank of Type Culture Collection of Shanghai Institute of Cell Biology, Chinese Academy of Sciences, and were authenticated by the providers by DNA-fingerprinting analysis or isoenzyme analysis. All of the cell lines were used at previous passages, (17) (18) (19) (20) and no morphological change or altered growth rate was observed during maintenance of cultures. Cell lines were routinely maintained at 378C in an atmosphere containing 5% CO 2 in Dulbecco's modified Eagle's medium supplemented with 10% FBS (Gibco, Thermo Fisher Scientific, Waltham, MA) and 1% penicillin-streptomycin. Cells were passed every 1-2 days to maintain logarithmic growth. For in vitro study, lentiviral (LV) vectors containing the human ALDH2 gene, green fluorescent protein (GFP), or ALD-H2(E504K) were constructed and designated as "LV-ALDH2," "LV-GFP," or "LV-ALDH2(E504K)." LV production was purchased from the Genechem Company (Shanghai, China). HCC-LM3 and SMMC-7721 cells were transfected with the specific virus at a multiplicity of infection of 20 in the presence of polybrene (6 lg/mL) for 8 hours. After 12 hours, the supernatant was replaced with cultured medium. Expression of ALDH2 in transfected cells was validated by qRT-PCR and western blotting. HCC-LM3 and SMMC-7721cells in a six-well plate were infected with small interfering RNAs (siRNAs; Biotend, Shanghai, China) against ALDH2 or AMPK using Lipofectamine2000 transfection reagent (Invitrogen, USA) to knock down ALDH2 or AMPK according to the manufacturer's instructions. A control siRNA was used as a negative control.
STATISTICAL ANALYSIS
RNA-Seq raw data analysis was performed according to the methods described in our previous report. (11) The iTRAQ (isobaric tags for relative and absolute quantitation) was performed by Shanghai Applied Protein Technology. The raw data were mapped to was performed with the R package "ROCR" (https:// www.r-project.org/). The correlation between clinical variables and ALDH2 expression were analyzed by two-tailed Fisher's exact test by R. For survival analysis, the ALDH2-high/low group was divided by median expression level. The Cox multivariate hazard regression model and survival analysis were performed using the R package "survival." See the Supporting Materials and Methods section for more details of these procedures.
Results
TRANSCRIPTOMICS AND PROTEOMICS REVEAL THAT ALDH2 LEVELS WERE GENERALLY DECREASED IN HCC TISSUES
To screen for alterations in gene expression during hepatocarcinogenesis and metastasis, we performed RNA-seq analysis using paired tumor and nontumor tissues that were obtained from 50 patients with HCC. We evaluated expression levels of over 20,000 genes. Among these, 13 samples were identified as MAH, and 14 were identified as MIH. We measured protein expression levels using the iTRAQ technique on equally mixed MAH/MIH normal/tumor tissues (referred to as MAH-normal, MAH-tumor, MIHnormal, and MIH-tumor). Three replicates were performed for each experiment. In all, 3,904 proteins were detected and uniquely identified in these four samples (12 replicates), and the overall correlation between the replicates was approximately 0.8 (Supporting Fig. S1) .
At the mRNA level, genes were up-or downregulated in more than 98% of the tumor tissues that were retained for further analysis, and 502 such genes were identified. At the protein level, genes that produced differentially expressed proteins in both MAH normal/tumor pairs and MIH normal/tumor pairs were retained, and they showed the same regulatory trend (e.g., up-or down-regulation) as their genes. A total of 348 such genes were identified. Genes that were differentially expressed between the MAH and MIH groups at both the mRNA and protein level were also evaluated, and 1,798 and 352 genes and proteins, respectively, were identified. We combined the results and found that four genes, ALDH2, cytochrome P450 2B6 (CYP2B6), dicarbonyl/L-xylulose reductase (DCXR), and glycine-N-acyltransferase-like 1 (GLYATL1), were differentially expressed in all of the groups (Fig. 1A) . ALDH2 catalyzes acetaldehyde, which is an intermediate metabolic product of alcohol, into acetic acid, and expression of ALDH2 was expressed at lower levels at both the mRNA and protein level in tumor tissues than in normal tissues and in MIH tissues than in MAH tissues (Fig. 1B-D) .
EXPRESSION OF ALDH2 WAS FREQUENTLY DOWN-REGULATED IN HUMAN HCC TISSUES AND INVASIVE HCC CELL LINES
To identify whether changes occur in ALDH2 expression during HCC development, we first performed a qRT-PCR analysis of 92 HCC samples. We found that ALDH2 expression was frequently (77.2%) expressed at lower levels in tumor tissues than in matched adjacent nontumor liver tissues ( Fig. 2A and Supporting Fig. S2A ). This finding was consistent with our RNA-seq analysis (98%; Fig. 1B ). The diagnostic value of ALDH2 was evaluated using an ROC curve, and the AUC (area under curve) reached 0.72 (Supporting Fig. S2B ). These findings were also consistent with the RNA-seq data (AUC 5 0.978; Supporting Fig. S2C ), indicating that ALDH2 is a potentially valuable biomarker for diagnosing HCC. Western blotting assays and IHC staining showed that the protein level of ALDH2 was also lower in HCC tumor tissues than in their matched counterparts (Fig.  2B,C) . We also found that ALDH2 expression levels were more reduced in patients with MIH, in those with primary HCC and venous metastases (e.g., PVTT) or in those with confirmed extrahepatic metastases at follow-up than in those with MAH (Fig. 2D) . Previous studies have shown that PVTT is the primary route by which metastasis occurs in patients with HCC, and that PVTT is strongly correlated with poor prognoses in HCC patients. (21) We next examined expression of ALDH2 in PVTT, tumor, and peritumoral tissues in each sample. We found that the mRNA and protein levels of ALDH2 were significantly lower in PVTT tissues than in the corresponding matched tumor or peritumoral tissues (Fig. 2E,F) . These results suggest that ALDH2 might play an important role in suppressing HCC progression.
Furthermore, to study expression levels of ALDH2 in HCC cells, three HCC cell lines and one normal liver cell line (L02) were analyzed using western blotting assays. Consistent with the results in other tissues, we observed that ALDH2 expression levels were higher in the normal liver cell line (L02) and the lessaggressive HCC cell lines (PLC/PRF/5) than in the more malignant liver cancer cell lines (SMMC-7721, HCC-LM3, and PVTT; Supporting Fig. S2D ).
DECREASED EXPRESSION LEVELS OF ALDH2 PREDICT AGGRESSIVE CLINICOPATHOLOGICAL TRAITS AND A POOR PROGNOSIS IN HCC PATIENTS
To better define the significance of the contribution of ALDH2 to the development and progression of HCC, all HCC patients from three data sets (the RNA-seq data set, RT-PCR data set and The Cancer Genome Atlas data set) were divided into two groups according to the median mRNA expression level of ALDH2 in the tumor tissues: a high ALDH2 expression group and a low ALDH2 expression group. The details of the clinicopathological characteristics of the patients are listed in Table 1 and Supporting Table  S1 . The patients in the ALDH-high group achieved better overall survival (OS) and a longer time to metastasis than the rates that were observed in the ALDH2-low group (Fig. 3A,B) . In addition, there was significant correlation between lower levels of ALDH2 and several aggressive clinicopathological traits, including extrahepatic metastasis (P < 0.01), microvascular invasion (P < 0.01), embolus (P < 0.05), older age (P < showed that the down-regulation of ALDH2 may be an independent prognostic factor for OS (Cox multivariate proportional hazard regression model). The HRs are presented as the means (with 95% confidence intervals). The variables included in the multivariate analysis were selected using a univariate analysis. (E) TTR were significantly different between the low-and high-ALDH2-expressing groups of HCC patients (2-sided log-rank test) in the RNA-seq data set. 0.05), and larger tumor size (P < 0.01; Fig. 3C ), which has been previously reported to be associated with a poor prognosis following primary resection surgery in HCC patients. (17) The multivariate analysis further indicated that ALDH2 expression levels were an independent risk factor for OS in patients with HCC showing intrahepatic metastases in the HCCLM3-GFP and HCCLM3-ALDH2 groups. Images were acquired using an IVIS Imaging System. Right panel: The number of lung metastatic foci in each group is presented as the mean 6 SD (error bars). *P < 0.05 (2-sided Student t test). (Fig. 3D) . In addition, patients with lower ALDH2 expression levels achieved shorter tumor-free survival times (Fig. 3E) . Taken together, these results suggest that ALDH2 expression levels may be an independent biomarker that predicts prognoses in HCC.
ECTOPICALLY EXPRESSING ALDH2 AMELIORATES METASTASIS IN HCC CELLS IN VITRO
Because we identified a significant correlation between ALDH2 expression levels and clinical invasive characteristics in HCC patients, it is probable that ALDH2 plays a protective role against cancer metastasis. Next, to explore the biological functions of ALDH2 in HCC in vitro, we used a lentivirus that encoded ALDH2 to establish ALDH2 stable cell lines: SMMC-7721 and HCCLM3 cells (referred to as SMMC7721-ALDH2 and HCCLM3-ADH2, respectively). Both lines expressed lower levels of endogenous ALDH2. Expression of ALDH2 was evaluated using western blotting analysis (Supporting Fig. S2E ). Scratch wound healing, migration, and Matrigel invasion assays were performed using these ALDH2-overexpressing cell lines, and the results revealed that dramatically less cell migration and invasion were observed in cells that ectopically expressed ALDH2 than in control cells expressing an LV GFP (HCCLM3-GFP and SMMC7721-GFP; Fig. 4A -C and Supporting Fig. S3A,B) . Additionally, cell growth analyses were also performed in which we used the Cell Counting Kit-8 and found that ALDH2 did not influence hepatoma cell growth (Supporting Fig.  S3C ).
To verify that ALDH2 affects cell migration and invasion, we next examined whether an ALDH2-specific siRNA (siALDH2; Supporting Fig. S3D ) affected cell motility. We found that silencing The migration and invasion ability of ALDH2-overexpression and their control cells was enhanced by treating with Compound C (CC, 5lM) for 15m. All treatment experiments were performed in triplicate. *P < 0.05; **P < 0.01. (F) The GSH content in HCCLM3-ALDH2 and SMMC7721-ALDH2 cells was compared to the content in HCCLM3-GFP and SMMC7721-GFP cells, respectively. Cells were grown in DMEM medium containing 10% FBS. Three independent experiments were performed (**P < 0.01).
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ALDH2 by transfecting a chemically synthesized siRNA specific for ALDH2 into cells stably expressing ALDH2 (referred to as HCCLM3-ALDH2 SMMC7721-ALDH2) resulted in significantly higher levels of migration in transfected cells than was observed in control cells (Fig. 4D-F and Supporting  Fig. S3E,F) . These results suggest that ALDH2 reduces the migratory and invasive capacity of HCC cells in vitro.
Previous studies have shown that ALDH activity reduced in a number of disease states. (22, 23) Here, we found that activity of ALDH2 was increased after ALDH2 overexpression (Supporting Fig. S4A ). In addition, we also found that transfecting LV vectors that contained the human ALDH2 mutation (rs671, E504K) gene into the HCC-LM3 cell line had no influence on enzyme activity or migratory ability (Supporting Fig. S4B,C) . It is plausible to speculate that it is not the level of ALDH2, but the activity of ALDH2 that is governing the HCC risk.
ECTOPIC EXPRESSION OF ALDH2 AMELIORATES METASTASIS IN HCC CELLS IN VIVO
To confirm the above in vitro findings in vivo, we first injected SMMC7721-GFP and SMMC7721-ALDH2 cells into the lateral tail veins of nude mice to establish a lung metastasis model. We then evaluated both metastatic growth in lungs and survival rates. Visual, in vivo imaging and microscopic evaluations of metastatic growth in lungs of nude mice showed that at 100 days postinjection, fewer and smaller foci were detected in the mice with ectopic ALDH2 (SMMC7721-GFP mean, 21 metastatic nodules per lung vs. SMMC7721-ALDH2 mean, five metastatic nodules per lung; Fig.  5A-C) . In addition, mice injected with SMMC7721-ALDH2 cells had significantly higher survival rates (GFP group vs. ALDH2 group: 77.8% vs. 22.2%, respectively; P 5 0.026, with a 100-day cutoff; Fig. 5D ). We then inoculated HCCLM3-GFP and HCCLM3-ALDH2 cells into mouse spleens to perform the hepatic metastasis assay. We measured metastatic tumor colonies in the liver 12 weeks later. The nude mice that were inoculated in the spleen with HCCLM3-ALDH2 cells displayed fewer and smaller xenografts in the liver than were observed in their controls (Fig. 5E,F) . Taken together, these findings indicate that ALDH2 is capable of modulating the aggressive, highly metastatic phenotype of HCCs in vivo.
ALDH2 ACTIVATES AMP-ACTIVATED PROTEIN KINASE SIGNALING IN HCC THROUGH A REDOX-DEPENDENT MECHANISM
To probe the molecular mechanisms underlying the ALDH2-mediated attenuation of HCC metastasis, we first probed the relationship between ALDH2 and epithelial mesenchymal transition (EMT) genes, which are key to tumor metastasis. However, we observed no significant alteration in cadherin levels or changes in cell morphology in response to ALDH2 induction, indicating that ALDH2-mediated attenuation of HCC metastasis is EMT independent (Fig.  6A) . Matrix metalloproteinases, which degrade extracellular matrix components, thereby facilitating the spread of tumor cells, (24) were also not affected by ALDH2 (Supporting Figure S5A) . Finally, no significant changes were detected in expression of the analyzed Glycolytic pathway genes (Supporting Fig.  S5B ).
We next analyzed the expression profile of HCCLM3-ALDH2 cells using a gene microarray platform. Differentially expressed genes were subsequently included in a functional classification analysis. A total of 106 genes were significantly up-regulated, whereas 49 genes were down-regulated (Fig. 6B) . Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses showed that several pathways were modulated when ALDH2 was up-regulated (data not shown). Although they were not significantly enriched, according to Ingenuity Pathway Analysis, expression levels of the AMP-activated protein kinase (AMPK) signaling pathway genes, cAMP responsive element-binding protein (CREB) 3, CREB5, and cholinergic receptor, nicotinic, epsilon (muscle), were significantly altered.
In addition, we found that phosphorylation of AMPK was clearly increased in both the HCCLM3-ALDH2 and SMMC7721-ALDH2 cell lines, whereas levels of phosphorylated extracellular signalregulated kinase (p-ERK) and phosphorylated c-Jun N-terminal kinase (p-JNK) were not increased between cells that stably expressed ALDH2 and control cells (Fig. 6C) . We also found that silencing ALDH2 by transfecting siALDH2 into cells stably expressing ALDH2 (HCCLM3-ALDH2, SMMC7721-ALDH2) resulted in significantly less AMPK activity than was observed in control cells (Fig. 6D) . Moreover, silencing ALDH2 by transfecting siALDH2 into PLC/PRF/5 cells (which express relatively high levels of ALDH2) also resulted in significantly less AMPK activity (Supporting Fig. S5C ). To further evaluate whether the AMPK signaling pathway is necessary for ALDH2-mediated suppression of HCC metastasis, we transiently transfected HCC-LM3 cells with a plasmid containing full-length ALDH2 (pcDNA3.1-ALDH2) or a control vector (pCDNA3.1), as described in the Materials and Methods section. We found that AMPK was activated in samples that expressed increased levels of ALDH2 (Fig. 6E) . Furthermore, we observed that protein levels of phosphorylated AMPK (p-AMPK) were significantly lower in PVTT tissues than in the corresponding matched tumor or peritumoral tissues (Fig. 6F ).
ALDH2 INHIBITS METASTASIS IN HCC CELLS BY REGULATING AMPK SIGNALING
To further investigate whether activation of p-AMPK is essential to ALDH2-mediated inhibition of HCC cell metastasis, we either activated or inhibited p-AMPK in HCC cell lines. Metformin (Met), a drug that is widely prescribed to treated type 2 diabetes, is known to promote AMPK in a variety of tissues. (25) There was a marked increase in activation of p-AMPK and inhibition of metastasis in both ALDH2-overexpressing cells and control cells that were treated with Met (Fig. 7A,B and Supporting Fig. S5D,E) . Another AMPK-specific activator, AICAR (5-aminoimidazole-4-carboxamide 1-b-D-ribofuranoside), also induced a similar inhibitory effect on the migratory and invasive capacity of HCCLM3-ALDH2 cells and their respective control cells (Fig. 7A,B and Supporting Fig. S5D,E) . Next, we examined whether knocking down AMPK by transiently transfecting cells with an siRNA specifically designed to inhibit AMPK expression would influence cell metastasis. We found that knocking down AMPK expression substantially blocked the inhibitory effects of ALDH2 on HCC cell migration and invasion ( Fig. 7C and Supporting Figs. S5F and S6A). In addition, we observe a similar effect on the ALDH2-mediated inhibition of migration and invasion when cells were treated with a specific AMPK inhibitor, Compound C (Fig. 7D,E and Supporting Fig. S6B ). Taken together, these data reveal that ALDH2 Inhibits metastasis in HCC cells largely by activating AMPK signaling.
Additionally, ALDH2 is the second enzyme in the major oxidative pathway involved in alcohol metabolism, during which ACE is removed. We therefore speculated that the ACE removal rate would be enhanced when ALDH2 was overexpressed. The level of ACE production was markedly lower in ALDH2-overexpression cells, which resulted in the removal of the reducing agent, nicotinamide adenine dinucleotide (Supporting Fig. S6C) . A higher level of intracellular redox was then observed in both HCCLM3-ALDH2 and SMMC-7721-ALDH2 cells than in their counterparts (Fig. 7F) . It was previously reported that AMPKa contains redox-sensitive cysteines that are rapidly oxidized during oxidative stress. (26) We therefore hypothesized that ALDH2 may activate AMPK signaling in HCC partly through a redox-dependent mechanism. Although it is possible that ACEs could also promote the migratory capacity of HCC cells, no significant difference was observed in the ALDH2-overexpressing cells that were treated with ACE (Supporting Fig. S6D,E) .
Discussion
Despite the fact that treatment strategies for HCC continue to evolve, prognoses in patients with HCC remain unsatisfactory because a major hallmark of HCC is its high recurrence and metastasis rates. (27, 28) Understanding the mechanisms underlying HCC development and progression would facilitate the development of effective treatment strategies aimed at reducing HCC-associated mortality. However, the gene expression signatures were significantly different between metastasis-free primary HCC and HCC accompanied by intrahepatic or distant metastases. (16) Therefore, more-reliable biomarkers are needed to predict HCC progression and achieve optimal medical management strategies.
To identify genes that may be essential for HCC progression, we performed a comprehensive global gene profile analysis of HCC and integrated the results with transcriptomic and proteomic data, and we demonstrated that livers bearing metastatic HCC also have a significantly different gene expression profile than livers bearing nonmetastatic HCC. Importantly, we found that ALDH2 levels were frequently lower in tumor tissues than in matched adjacent nontumor tissues and in MIH tissues than in MAH tissues at both the mRNA and protein level.
It has previously been shown that aberrant ALDH2 expression plays a critical role in the pathogenesis of different human diseases. (12) For example, individuals who carry a functional variant of ALDH2 have a higher baseline risk of developing esophageal cancer in a Japanese population. (29) Also, it was previously reported that the functional ALDH2 enzyme needs a tetramer to be active, (30) and if any of the four subunits is the defective Lys504 isotype, ALDH2 activity will be severely compromised. (31, 32) In addition, ALDH2 activity substantially contributes to a more-efficacious clinical response to glyceryl trinitrate in angina and heart failure patients, (33) and an ALDH2 gene quantity detection kit is already available on the medical service market. However, the role of ALDH2 in the pathogenesis of HCC remains controversial. (21, 34) In the present study, we focused on evaluating the expression and physiological functions of ALDH2 during tumor progression rather than its epidemiological consequences in HCC.
We first analyzed ALDH2 expression levels in human HCC samples and cell lines in addition to evaluating the role of ALDH2 in the progression of HCC. Our results indicate that ALDH2 is frequently expressed at lower levels in clinical HCC samples, even when the livers bear metastatic HCC, and in invasive HCC cell lines. Additionally, we found that there is a negative correlation between ALDH2 mRNA expression levels and malignant HCC characteristics in independent HCC cohorts. A multivariate analysis further indicated that the expression level of ALDH2 was an independent risk factor for overall survival. In addition, ectopically expressing ALDH2 dramatically suppressed HCC migration and invasion both in vitro and in vivo. And ALDH2 activity assay showed it could not be the level of ALDH2, but the activity of ALDH2 that is governing the HCC risk. Taken together, these results indicate that ALDH2 plays an important antimetastatic role in HCC and can be used to predict HCC prognoses. Furthermore, manipulations of ALDH2 levels may serve as novel therapeutic strategies to treat HCC.
Previous studies have demonstrated that AMPK is a sensor of cellular and whole-body energy homeostasis, (35, 36) and that it plays an important role in linking metabolism and cancer development. AMPK can be activated by change in intracellular redox status because it possesses redox-sensitive cysteines. (26) It can also be activated by the antidiabetic drug, Met, in addition to cytokines and hormones. (37, 38) Once activated, AMPK regulates energy usage to ensure cell survival. (39) In recent years, a wide variety of studies have documented that AMPK is involved in cancer cell metabolism and growth. (40) By regulating a large number of downstream targets, AMPK controls intracellular energy usage and contributes to the maintenance of proper growth rates. (41) Inactivation of AMPK has been associated with tumorigenesis and malignant features in several cancers, including breast, lung, and prostate cancer. These data collectively indicate that AMPK is a promising target for cancer therapies.
In this study, we found that ectopically expressing ALDH2 enhanced the ACE removal rate, thereby increasing intracellular redox level. Additionally, ALDH2 activated phosphorylation of AMPK through a redox-dependent mechanism. Furthermore, we observed that Met, a widely used antidiabetic drug, enhanced ALDH2-mediated inhibition of cell metastasis by activating p-AMPK. Another AMPK activator, AICAR, had the same influence on ALDH2-mediated cell metastasis. Finally, knocking down AMPK using a specific siRNA or inhibitor (Compound C) further confirmed our results.
In summary, the results described in this study reveal that ALDH2 plays an important role in protecting against HCC metastasis, and the forced expression of ALDH2 in HCC cells inhibited cell migration and invasion both in vitro and in vivo, at least partly by modulating the ALDH2-ACE redox-AMPK axis. These findings may facilitate the development of strategies for classifying patients to provide therapeutic options in which MIM profiles are converted to MAM profiles to prevent the development of metastatic HCC.
